Biotech

All Articles

Lilly blog posts extra favorable records on its own every week the hormone insulin possibility

.On the heels of an FDA being rejected for its chief rival Novo Nordisk, Eli Lilly is pushing on in ...

IN 8bio halts stage 2 trial, gives up fifty percent of staff

.Merely a couple of months after application the 1st person in a phase 2 test for recently diagnosed...

Lilly, Haya ink $1B biobuck being overweight deal to search black genome

.Eli Lilly's hunt for weight problems intendeds has actually led it to the black genome. The Big Pha...

ArsenalBio elevates $325M, pivots away from past lead possession

.Collection Biosciences is carrying on up. The cell therapy firm has added $325 thousand in ammo alo...

Lilly- backed effective weight loss biotech reports IPO

.After raising $170 thousand back in February, metabolic disease-focused BioAge Labs has filed to de...

Aelis' marijuana use drug flunks stage 2b, driving Indivior to reconsider $100M alternative

.Aelis Farma's hopes of protecting a simple, good selection on a $one hundred thousand option remitt...

ProKidney halts phase 3 trial certainly not needed for cell treatment approval

.ProKidney has actually ceased some of a pair of period 3 tests for its own tissue treatment for kid...

Vaxcyte rises on 'remarkable' 31-valent PCV gain versus Pfizer

.Vaxcyte revealed what experts referred to as "sensational" phase 1/2 data for its 31-valent pneumoc...

Recursion's mind condition trial presents insufficient proof of efficacy

.Recursion has stumbled with a very early examination of its tech-enabled method to medicine explora...

Acepodia, Pfizer click together for chemistry-based tissue therapy

.Contact it a scenario of really good chemical make up: Acepodia, a biotech based on Nobel Prize-win...